Refining adjuvant therapy for non-metastatic colon cancer,new standards and perspectives |
| |
| Affiliation: | 1. Department of gastroenterology and GI Oncology, Georges-Pompidou European Hospital, AP-HP; Sorbonne Paris cité, Université de Paris, Paris, France;2. Département de chirurgie viscérale oncologique, Gustave Roussy, Villejuif, France;3. Pole biologie, Hospital European George Pompidou, Paris, Île-de-France, France;4. Fédération Francophone de Cancérologie Digestive; EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France;5. EA4340, Ambroise Pare Hospital, Beuvry, Hauts-de-France, France;6. Gastroenterology Department and Medical Oncology Department, Poitiers University Hospital, Poitiers, France;7. Department of Gastroenterology, Groupement hospitalier Sud, Hospices civils de Lyon, Pierre Bénite, France;8. Centre de Recherche des Cordeliers, INSERM, CNRS, Sorbonne Université, USPC, Université de Paris, Equipe labellisée Ligue Nationale contre le cancer, Paris, France.;9. Department of digestive oncology University hospital Dijon; University of Burgundy and Franche Comté, Dijon, France;10. Sorbonne Université and Hôpital Saint Antoine, Paris, France |
| |
| Abstract: | Colon cancer is the third most frequent cancer in males and the second in females. Approximately 75% are diagnosed at a localized stage. Recurrence occurs in 30% of patients when there is nodal involvement (stage III) due to micrometastatic spreading. To date only chemotherapeutic drugs such as fluoropyrimidines or oxaliplatin have proven effective to kill this residual disease and are currently recommended by scientific societies. To improve patient management in the near future, recent research has focused on new ways of using currently available agents, tools to better define each individual patient prognosis more clearly so as to tailor adjuvant treatment, and molecular profiling to identify specific subgroups of patients with tumors that may benefit from specific therapeutic approaches. In this review, we will focus on current scientific knowledge on adjuvant treatment in localized colon cancer, the duration and timing of adjuvant therapy and the perspectives for better selection of patients who will benefit from adjuvant treatments. |
| |
| Keywords: | Colon cancer Adjuvant Survival Prognosis |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
